ID   PAPS2_HUMAN             Reviewed;         614 AA.
AC   O95340; Q9BZL2; Q9P0G6; Q9UHM1; Q9UKD3; Q9UP30;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   12-APR-2017, entry version 169.
DE   RecName: Full=Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2;
DE            Short=PAPS synthase 2;
DE            Short=PAPSS 2;
DE   AltName: Full=Sulfurylase kinase 2;
DE            Short=SK 2;
DE            Short=SK2;
DE   Includes:
DE     RecName: Full=Sulfate adenylyltransferase;
DE              EC=2.7.7.4;
DE     AltName: Full=ATP-sulfurylase;
DE     AltName: Full=Sulfate adenylate transferase;
DE              Short=SAT;
DE   Includes:
DE     RecName: Full=Adenylyl-sulfate kinase;
DE              EC=2.7.1.25;
DE     AltName: Full=3'-phosphoadenosine-5'-phosphosulfate synthase;
DE     AltName: Full=APS kinase;
DE     AltName: Full=Adenosine-5'-phosphosulfate 3'-phosphotransferase;
DE     AltName: Full=Adenylylsulfate 3'-phosphotransferase;
GN   Name=PAPSS2; Synonyms=ATPSK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Fetal cartilage;
RX   PubMed=9771708; DOI=10.1038/2458;
RA   ul Haque M.F., King L.M., Krakow D., Cantor R.M., Rusiniak M.E.,
RA   Swank R.T., Superti-Furga A., Haque S., Abbas H., Ahmad W., Ahmad M.,
RA   Cohn D.H.;
RT   "Mutations in orthologous genes in human spondyloepimetaphyseal
RT   dysplasia and the brachymorphic mouse.";
RL   Nat. Genet. 20:157-162(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RA   Franzon V.L., Gibson M.A., Hatzinikolas G., Cleary E.G., Woolatt E.,
RA   Sutherland G.R.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RA   Fuda H., Shimizu C., Strott C.A.;
RT   "Human bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase:
RT   differential expression of isoforms and effect of polymorphisms on
RT   activity.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM A).
RX   PubMed=10679223; DOI=10.1006/bbrc.2000.2123;
RA   Xu Z.-H., Otterness D.M., Freimuth R.R., Carlini E.J., Wood T.C.,
RA   Mitchell S., Moon E., Kim U.-J., Xu J.-P., Siciliano M.J.,
RA   Weinshilboum R.M.;
RT   "Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1) and
RT   PAPSS2: gene cloning, characterization and chromosomal localization.";
RL   Biochem. Biophys. Res. Commun. 268:437-444(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Liver;
RX   PubMed=10559207; DOI=10.1074/jbc.274.47.33306;
RA   Kurima K., Singh B., Schwartz N.B.;
RT   "Genomic organization of the mouse and human genes encoding the ATP
RT   sulfurylase/adenosine 5'-phosphosulfate kinase isoform SK2.";
RL   J. Biol. Chem. 274:33306-33312(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Venkatachalam K.V., Fuda H., Strott C.A.;
RT   "3'-phosphoadenosine 5'-phosphosulfate synthase 2b isoform.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INVOLVEMENT IN BCYM4.
RX   PubMed=9714015;
RX   DOI=10.1002/(SICI)1096-8628(19980806)78:5<468::AID-AJMG13>3.0.CO;2-D;
RA   Ahmad M., Haque M.F., Ahmad W., Abbas H., Haque S., Krakow D.,
RA   Rimoin D.L., Lachman R.S., Cohn D.H.;
RT   "Distinct, autosomal recessive form of spondyloepimetaphyseal
RT   dysplasia segregating in an inbred Pakistani kindred.";
RL   Am. J. Med. Genet. 78:468-473(1998).
RN   [9]
RP   TISSUE SPECIFICITY, VARIANT BCYM4 ARG-48, AND CHARACTERIZATION OF
RP   VARIANT BCYM4 ARG-48.
RX   PubMed=19474428; DOI=10.1056/NEJMoa0810489;
RA   Noordam C., Dhir V., McNelis J.C., Schlereth F., Hanley N.A.,
RA   Krone N., Smeitink J.A., Smeets R., Sweep F.C.,
RA   Claahsen-van der Grinten H.L., Arlt W.;
RT   "Inactivating PAPSS2 mutations in a patient with premature pubarche.";
RL   N. Engl. J. Med. 360:2310-2318(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 21-218 IN COMPLEX WITH ATP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the kinase domain of PAPSS 2.";
RL   Submitted (SEP-2005) to the PDB data bank.
RN   [13]
RP   VARIANTS LYS-10; LEU-281; MET-291 AND LYS-432, AND CHARACTERIZATION OF
RP   VARIANTS LYS-10 AND MET-291.
RX   PubMed=11773860; DOI=10.1097/00008571-200201000-00003;
RA   Xu Z.-H., Freimuth R.R., Eckloff B., Wieben E., Weinshilboum R.M.;
RT   "Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2)
RT   pharmacogenetics: gene resequencing, genetic polymorphisms and
RT   functional characterization of variant allozymes.";
RL   Pharmacogenetics 12:11-21(2002).
RN   [14]
RP   INVOLVEMENT IN BCYM4.
RX   PubMed=23633440; DOI=10.1002/ajmg.a.35906;
RA   Tueysuez B., Yilmaz S., Guel E., Kolb L., Bilguvar K., Evliyaoglu O.,
RA   Guenel M.;
RT   "Spondyloepimetaphyseal dysplasia Pakistani type: expansion of the
RT   phenotype.";
RL   Am. J. Med. Genet. A 161A:1300-1308(2013).
RN   [15]
RP   VARIANTS BCYM4 TYR-43 AND GLN-76, CHARACTERIZATION OF VARIANTS BCYM4
RP   TYR-43 AND GLN-76, VARIANT LYS-183, AND CHARACTERIZATION OF VARIANT
RP   LYS-183.
RX   PubMed=23824674; DOI=10.1002/humu.22377;
RA   Iida A., Simsek-Kiper P.O., Mizumoto S., Hoshino T., Elcioglu N.,
RA   Horemuzova E., Geiberger S., Yesil G., Kayserili H., Utine G.E.,
RA   Boduroglu K., Watanabe S., Ohashi H., Alanay Y., Sugahara K.,
RA   Nishimura G., Ikegawa S.;
RT   "Clinical and radiographic features of the autosomal recessive form of
RT   brachyolmia caused by PAPSS2 mutations.";
RL   Hum. Mutat. 34:1381-1386(2013).
RN   [16]
RP   VARIANT BCYM4 ASP-270, AND CHARACTERIZATION OF VARIANTS BCYM4 ARG-48
RP   AND ASP-270.
RX   PubMed=25594860; DOI=10.1210/jc.2014-3556;
RA   Oostdijk W., Idkowiak J., Mueller J.W., House P.J., Taylor A.E.,
RA   O'Reilly M.W., Hughes B.A., de Vries M.C., Kant S.G., Santen G.W.,
RA   Verkerk A.J., Uitterlinden A.G., Wit J.M., Losekoot M., Arlt W.;
RT   "PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation
RT   - in vitro and in vivo studies in a family harboring two novel PAPSS2
RT   mutations.";
RL   J. Clin. Endocrinol. Metab. 2015:JC20143556-JC20143556(2015).
CC   -!- FUNCTION: Bifunctional enzyme with both ATP sulfurylase and APS
CC       kinase activity, which mediates two steps in the sulfate
CC       activation pathway. The first step is the transfer of a sulfate
CC       group to ATP to yield adenosine 5'-phosphosulfate (APS), and the
CC       second step is the transfer of a phosphate group from ATP to APS
CC       yielding 3'-phosphoadenylylsulfate (PAPS: activated sulfate donor
CC       used by sulfotransferase). In mammals, PAPS is the sole source of
CC       sulfate; APS appears to be only an intermediate in the sulfate-
CC       activation pathway. May have a important role in skeletogenesis
CC       during postnatal growth (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + sulfate = diphosphate + adenylyl
CC       sulfate.
CC   -!- CATALYTIC ACTIVITY: ATP + adenylyl sulfate = ADP + 3'-
CC       phosphoadenylyl sulfate.
CC   -!- PATHWAY: Sulfur metabolism; sulfate assimilation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=O95340-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=O95340-2; Sequence=VSP_001259;
CC   -!- TISSUE SPECIFICITY: Expressed in cartilage and adrenal gland.
CC       {ECO:0000269|PubMed:19474428}.
CC   -!- DISEASE: Brachyolmia type 4 with mild epiphyseal and metaphyseal
CC       changes (BCYM4) [MIM:612847]: A form of brachyolmia, a clinically
CC       and genetically heterogeneous skeletal dysplasia primarily
CC       affecting the spine and characterized by a short trunk, short
CC       stature, and platyspondyly. BCYM4 is an autosomal recessive form
CC       with mild epiphyseal and metaphyseal changes. Clinical features
CC       include short stature evidenced at birth, short and bowed lower
CC       limbs, mild brachydactyly, kyphoscoliosis, abnormal gait, enlarged
CC       knee joints. Some BCYM4 patients may manifest premature pubarche
CC       and hyperandrogenism associated with skeletal dysplasia and short
CC       stature. {ECO:0000269|PubMed:19474428,
CC       ECO:0000269|PubMed:23633440, ECO:0000269|PubMed:23824674,
CC       ECO:0000269|PubMed:25594860, ECO:0000269|PubMed:9714015}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the APS kinase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the sulfate
CC       adenylyltransferase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF091242; AAC64583.1; -; mRNA.
DR   EMBL; AF074331; AAD38423.1; -; mRNA.
DR   EMBL; AF313907; AAK00296.1; -; mRNA.
DR   EMBL; AF160509; AAF40307.2; -; Genomic_DNA.
DR   EMBL; AF160503; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF160504; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF160505; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF160506; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF160507; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF160508; AAF40307.2; JOINED; Genomic_DNA.
DR   EMBL; AF173365; AAF12761.1; -; mRNA.
DR   EMBL; AF150754; AAF20366.2; -; mRNA.
DR   EMBL; BC009894; AAH09894.1; -; mRNA.
DR   CCDS; CCDS44453.1; -. [O95340-2]
DR   CCDS; CCDS7385.1; -. [O95340-1]
DR   RefSeq; NP_001015880.1; NM_001015880.1. [O95340-2]
DR   RefSeq; NP_004661.2; NM_004670.3. [O95340-1]
DR   UniGene; Hs.524491; -.
DR   PDB; 2AX4; X-ray; 2.50 A; A/B/C/D=21-218.
DR   PDBsum; 2AX4; -.
DR   ProteinModelPortal; O95340; -.
DR   SMR; O95340; -.
DR   BioGrid; 114521; 14.
DR   IntAct; O95340; 3.
DR   MINT; MINT-5000453; -.
DR   STRING; 9606.ENSP00000406157; -.
DR   iPTMnet; O95340; -.
DR   PhosphoSitePlus; O95340; -.
DR   SwissPalm; O95340; -.
DR   BioMuta; PAPSS2; -.
DR   EPD; O95340; -.
DR   PaxDb; O95340; -.
DR   PeptideAtlas; O95340; -.
DR   PRIDE; O95340; -.
DR   TopDownProteomics; O95340-1; -. [O95340-1]
DR   DNASU; 9060; -.
DR   Ensembl; ENST00000361175; ENSP00000354436; ENSG00000198682. [O95340-1]
DR   Ensembl; ENST00000456849; ENSP00000406157; ENSG00000198682. [O95340-2]
DR   GeneID; 9060; -.
DR   KEGG; hsa:9060; -.
DR   UCSC; uc001kew.4; human. [O95340-1]
DR   CTD; 9060; -.
DR   DisGeNET; 9060; -.
DR   GeneCards; PAPSS2; -.
DR   HGNC; HGNC:8604; PAPSS2.
DR   HPA; HPA071224; -.
DR   MalaCards; PAPSS2; -.
DR   MIM; 603005; gene.
DR   MIM; 612847; phenotype.
DR   neXtProt; NX_O95340; -.
DR   OpenTargets; ENSG00000198682; -.
DR   Orphanet; 93303; Brachyolmia type 1, Toledo type.
DR   Orphanet; 93282; Spondyloepimetaphyseal dysplasia, Pakistani type.
DR   PharmGKB; PA383; -.
DR   eggNOG; KOG0635; Eukaryota.
DR   eggNOG; KOG4238; Eukaryota.
DR   eggNOG; COG0529; LUCA.
DR   eggNOG; COG2046; LUCA.
DR   GeneTree; ENSGT00390000009613; -.
DR   HOVERGEN; HBG053503; -.
DR   KO; K13811; -.
DR   OMA; QHPYIKM; -.
DR   OrthoDB; EOG091G07ZR; -.
DR   PhylomeDB; O95340; -.
DR   TreeFam; TF313143; -.
DR   BioCyc; MetaCyc:HS07544-MONOMER; -.
DR   BRENDA; 2.7.1.25; 2681.
DR   Reactome; R-HSA-174362; Transport and synthesis of PAPS.
DR   Reactome; R-HSA-2408550; Metabolism of ingested H2SeO4 and H2SeO3 into H2Se.
DR   SABIO-RK; O95340; -.
DR   UniPathway; UPA00097; -.
DR   ChiTaRS; PAPSS2; human.
DR   EvolutionaryTrace; O95340; -.
DR   GeneWiki; PAPSS2; -.
DR   GenomeRNAi; 9060; -.
DR   PRO; PR:O95340; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000198682; -.
DR   CleanEx; HS_PAPSS2; -.
DR   ExpressionAtlas; O95340; baseline and differential.
DR   Genevisible; O95340; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004020; F:adenylylsulfate kinase activity; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016779; F:nucleotidyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0004781; F:sulfate adenylyltransferase (ATP) activity; ISS:UniProtKB.
DR   GO; GO:0050428; P:3'-phosphoadenosine 5'-phosphosulfate biosynthetic process; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0000103; P:sulfate assimilation; IEA:UniProtKB-UniPathway.
DR   CDD; cd02027; APSK; 1.
DR   CDD; cd00517; ATPS; 1.
DR   Gene3D; 3.40.50.620; -; 1.
DR   HAMAP; MF_00065; Adenylyl_sulf_kinase; 1.
DR   InterPro; IPR002891; APS_kinase.
DR   InterPro; IPR025980; ATP-Sase_PUA-like_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR015947; PUA-like_domain.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   InterPro; IPR024951; Sulfurylase_cat_dom.
DR   InterPro; IPR002650; Sulphate_adenylyltransferase.
DR   Pfam; PF01747; ATP-sulfurylase; 1.
DR   Pfam; PF14306; PUA_2; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF88697; SSF88697; 1.
DR   TIGRFAMs; TIGR00455; apsK; 1.
DR   TIGRFAMs; TIGR00339; sopT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Disease mutation; Dwarfism; Kinase;
KW   Multifunctional enzyme; Nucleotide-binding; Nucleotidyltransferase;
KW   Polymorphism; Reference proteome; Transferase.
FT   CHAIN         1    614       Bifunctional 3'-phosphoadenosine 5'-
FT                                phosphosulfate synthase 2.
FT                                /FTId=PRO_0000105961.
FT   NP_BIND      52     57       ATP 1. {ECO:0000244|PDB:2AX4,
FT                                ECO:0000269|Ref.12}.
FT   NP_BIND     409    412       ATP 2. {ECO:0000250|UniProtKB:O43252}.
FT   NP_BIND     511    515       ATP 2. {ECO:0000250|UniProtKB:O43252}.
FT   REGION        1    215       Adenylyl-sulfate kinase. {ECO:0000305}.
FT   REGION       79     82       Adenylyl sulfate binding.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   REGION       96     99       Adenylyl sulfate binding.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   REGION      122    123       Adenylyl sulfate binding.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   REGION      174    175       Adenylyl sulfate binding.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   REGION      224    614       Sulfate adenylyltransferase.
FT                                {ECO:0000305}.
FT   BINDING      91     91       Adenylyl sulfate.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   BINDING     161    161       Adenylyl sulfate.
FT                                {ECO:0000250|UniProtKB:O43252}.
FT   BINDING     197    197       ATP 1; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:2AX4,
FT                                ECO:0000269|Ref.12}.
FT   BINDING     553    553       ATP 2; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000250|UniProtKB:O43252}.
FT   MOD_RES       5      5       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q60967}.
FT   VAR_SEQ     288    288       D -> DGMALP (in isoform B).
FT                                {ECO:0000303|PubMed:10559207,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_001259.
FT   VARIANT      10     10       E -> K (significant decrease of activity;
FT                                dbSNP:rs17173698).
FT                                {ECO:0000269|PubMed:11773860}.
FT                                /FTId=VAR_029136.
FT   VARIANT      43     43       C -> Y (in BCYM4; reduces strongly PAPS
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:23824674}.
FT                                /FTId=VAR_073026.
FT   VARIANT      48     48       T -> R (in BCYM4; patient with premature
FT                                pubarche and hyperandrogenism; results in
FT                                partial loss of activity; increases
FT                                ubiquitin-dependent protein instability;
FT                                dbSNP:rs121908951).
FT                                {ECO:0000269|PubMed:19474428,
FT                                ECO:0000269|PubMed:25594860}.
FT                                /FTId=VAR_063049.
FT   VARIANT      76     76       L -> Q (in BCYM4; reduces strongly PAPS
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:23824674}.
FT                                /FTId=VAR_073027.
FT   VARIANT     183    183       E -> K (polymorphism; similar PAPS
FT                                synthase activity as the wild-type;
FT                                dbSNP:rs774709274).
FT                                {ECO:0000269|PubMed:23824674}.
FT                                /FTId=VAR_073028.
FT   VARIANT     270    270       G -> D (in BCYM4; increases ubiquitin-
FT                                dependent protein instability;
FT                                dbSNP:rs138943074).
FT                                {ECO:0000269|PubMed:25594860}.
FT                                /FTId=VAR_073029.
FT   VARIANT     281    281       M -> L (in dbSNP:rs45624631).
FT                                {ECO:0000269|PubMed:11773860}.
FT                                /FTId=VAR_029137.
FT   VARIANT     291    291       V -> M (significant decrease of activity;
FT                                dbSNP:rs45467596).
FT                                {ECO:0000269|PubMed:11773860}.
FT                                /FTId=VAR_022077.
FT   VARIANT     432    432       R -> K (in dbSNP:rs17129133).
FT                                {ECO:0000269|PubMed:11773860}.
FT                                /FTId=VAR_029138.
FT   CONFLICT    166    166       R -> K (in Ref. 2; AAD38423).
FT                                {ECO:0000305}.
FT   CONFLICT    361    361       E -> G (in Ref. 3; AAK00296).
FT                                {ECO:0000305}.
FT   CONFLICT    426    426       R -> C (in Ref. 1; AAC64583).
FT                                {ECO:0000305}.
FT   CONFLICT    567    567       P -> L (in Ref. 2; AAD38423).
FT                                {ECO:0000305}.
FT   HELIX        27     33       {ECO:0000244|PDB:2AX4}.
FT   STRAND       34     37       {ECO:0000244|PDB:2AX4}.
FT   STRAND       43     48       {ECO:0000244|PDB:2AX4}.
FT   HELIX        55     68       {ECO:0000244|PDB:2AX4}.
FT   STRAND       73     76       {ECO:0000244|PDB:2AX4}.
FT   HELIX        78     81       {ECO:0000244|PDB:2AX4}.
FT   TURN         82     88       {ECO:0000244|PDB:2AX4}.
FT   HELIX        93    112       {ECO:0000244|PDB:2AX4}.
FT   STRAND      116    120       {ECO:0000244|PDB:2AX4}.
FT   HELIX       126    138       {ECO:0000244|PDB:2AX4}.
FT   STRAND      143    149       {ECO:0000244|PDB:2AX4}.
FT   HELIX       152    158       {ECO:0000244|PDB:2AX4}.
FT   STRAND      160    162       {ECO:0000244|PDB:2AX4}.
FT   HELIX       163    168       {ECO:0000244|PDB:2AX4}.
FT   TURN        176    178       {ECO:0000244|PDB:2AX4}.
FT   STRAND      189    193       {ECO:0000244|PDB:2AX4}.
FT   HELIX       199    212       {ECO:0000244|PDB:2AX4}.
SQ   SEQUENCE   614 AA;  69501 MW;  52F4B6D972DDA91E CRC64;
     MSGIKKQKTE NQQKSTNVVY QAHHVSRNKR GQVVGTRGGF RGCTVWLTGL SGAGKTTISF
     ALEEYLVSHA IPCYSLDGDN VRHGLNRNLG FSPGDREENI RRIAEVAKLF ADAGLVCITS
     FISPFAKDRE NARKIHESAG LPFFEIFVDA PLNICESRDV KGLYKRARAG EIKGFTGIDS
     DYEKPETPER VLKTNLSTVS DCVHQVVELL QEQNIVPYTI IKDIHELFVP ENKLDHVRAE
     AETLPSLSIT KLDLQWVQVL SEGWATPLKG FMREKEYLQV MHFDTLLDDG VINMSIPIVL
     PVSAEDKTRL EGCSKFVLAH GGRRVAILRD AEFYEHRKEE RCSRVWGTTC TKHPHIKMVM
     ESGDWLVGGD LQVLEKIRWN DGLDQYRLTP LELKQKCKEM NADAVFAFQL RNPVHNGHAL
     LMQDTRRRLL ERGYKHPVLL LHPLGGWTKD DDVPLDWRMK QHAAVLEEGV LDPKSTIVAI
     FPSPMLYAGP TEVQWHCRSR MIAGANFYIV GRDPAGMPHP ETKKDLYEPT HGGKVLSMAP
     GLTSVEIIPF RVAAYNKAKK AMDFYDPARH NEFDFISGTR MRKLAREGEN PPDGFMAPKA
     WKVLTDYYRS LEKN
//
